BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical

www.prnewswire.com

BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical.

http://www.prnewswire.com/news-releases/biowa-announces-second-japanese-license-of-potelligentr-technology-to-otsuka-pharmaceutical-63555257.html

YM BioSciences Inc.

BIO InvestorForum 2008 When: October 30, 2008 / 2:15pm PDT Where: Palace Hotel, Sea Cliff Room - San Francisco, CA Sean Thompson, VP Corporate Development, will be presenting at this conference. [listen to webcast]

http://www.ymbiosciences.com/

YM BioSciences Inc. information and related industry information from Hoover's United Kingdom (UK)

The "YM" BioSciences might stand for "young and modern" as once the letters of YM magazine did. The firm was founded in 1994 to develop a variety of new anti-cancer technologies.

http://www.hoovers.com/ym-biosciences/--ID__119170--/freeuk-co-factsheet.xhtml

Description: The YM BioSciences Inc Financial Report contains the company’s contact information,...

Description: The YM BioSciences Inc Financial Report contains the company’s contact information, details, business overview, shares information, stock performance history, price and volume figures, dividends, market related data including relative strength, valuation and revenues.

http://www.researchandmarkets.co.uk/reports/332460/ym_biosciences_inc_financial_report.pdf

American Stock Exchange News Releases - AMERICAN STOCK EXCHANGE LISTS COMMON STOCK OF YM

YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator (for taxanes and anthracyclines) currently undergoing a pivotal Phase III trial in metastatic breast cancer.

http://www.amex.com/atamex/news/press/sn_YMI_100104.htm